A privately-held Cambridge, MA-based biotech called Strang Therapeutics recently secured funding from two Phase 1 Small Business Innovation Research (SBIR) grants from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to develop mRNA-based therapeutics for melanoma and triple-negative breast cancer (TNBC). Both grants total approximately $800,000.
Strand Therapeutics Background
Founded in 2017, this biotech venture has raised about $58 million, according to the website Crunchbase. A developer of a biotechnology platform intended to create gene therapies powered by synthetic biology, the company was founded by Darrell Irvine (MIT), Jacob Becraft (MIT), Ron Weiss (MIT), and Tasuku Kitada.
Key Therapeutic Areas
While there have been advances in the development of treatment options for melanoma, the number of diagnoses continues to increase. Furthermore, the standard of care using anti-PD-1 immunotherapy has been limited, with not all patients responding to the therapy. To address this need, the first award granted to Strand will support the development of programmable mRNA circuits that expr...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).